ニューキノロン薬balofloxacinのin vitro抗抗酸菌活性  [in Japanese] IN VITRO ANTIMYCOBACTERIAL ACTIVITIES OF A NEW QUINOLONE, BALOFLOXACIN  [in Japanese]

Access this Article

Author(s)

Abstract

Balofloxacin (BLFX), a newly developed fluoroquinolone, was studied for its in vitro antimycobacterial activity by the agar dilution method with 7H11 agar medium. The MIC<SUB>90</SUB>s were as follows: 0.39μg/m<I>l</I> for <I>M. tuberculosis</I>, '50μg/m<I>l</I> for <I>M. avium</I>, '50μ g/m<I>l</I> for <I>M. intracellulare</I>, 0.39μg/m<I>l</I> for <I>M. kansasii</I>, 0.39μg/m<I>l</I> for <I>M. fortuitum</I>, '50μg/m<I>l</I> for <I>M. abscessus</I>, and 50μg/m<I>l</I> for <I>M. chelonae</I>. The antimycobacterial activity of BLFX was comparable or slightly inferior to that of levofloxacin (LVFX). Considering the present findings and pharmacokinetics of BFLX, it appears that BFLX may achieve favorable outcome in the treatment of patients with infection due to <I>M. tuberculosis</I>, <I>M. kansasii</I>, or <I>M. fortuitum</I> similar to that of ofloxacin or LVFX.

Journal

  • Kekkaku(Tuberculosis)

    Kekkaku(Tuberculosis) 76(1), 29-31, 2001-01-15

    JAPANESE SOCIETY FOR TUBERCULOSIS

References:  7

Codes

  • NII Article ID (NAID)
    10008113048
  • NII NACSIS-CAT ID (NCID)
    AN00073442
  • Text Lang
    JPN
  • Article Type
    NOT
  • ISSN
    00229776
  • NDL Article ID
    026777387
  • NDL Call No.
    Z19-133
  • Data Source
    CJP  NDL  J-STAGE 
Page Top